Eli Lilly Grants Innovent Verzenios Rights in China, Expands Jaypirca in Europe

In late June 2026, Innovent Biologics announced a distribution and promotion agreement with Eli Lilly and Company (NYSE: LLY) granting it exclusive commercialization rights for the breast cancer drug Verzenios in mainland China. Lilly retains manufacturing, supply, and development responsibilities.

Details

Under the agreement, Innovent will market and promote Verzenios in China, while Lilly remains responsible for production, supply chain, and clinical development. Financial terms were not disclosed.

Separately, Eli Lilly received a positive regulatory opinion from the European Medicines Agency (EMA) to expand the use of Jaypirca to include adult patients with chronic lymphocytic leukemia (CLL) who have received prior therapy. Jaypirca was previously approved only for mantle cell lymphoma (MCL).

Context

These moves are part of Eli Lilly's strategy to strengthen its presence in international markets, particularly China, the world's second-largest pharmaceutical market. They also reflect the company's expansion in oncology, a key growth sector.

What It Means for Investors

These developments demonstrate Eli Lilly's commitment to broadening access to its drugs through partnerships and regulatory approvals. For LLY investors, these steps could boost future revenues, but execution and competition in the Chinese market should be monitored.